A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma
Latest Information Update: 01 Jul 2019
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary) ; Gemcitabine; Paclitaxel
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 01 Jul 2019 New trial record